AU2010237130B2 - Engineered mesenchymal stem cells and method of using same to treat tumors - Google Patents

Engineered mesenchymal stem cells and method of using same to treat tumors Download PDF

Info

Publication number
AU2010237130B2
AU2010237130B2 AU2010237130A AU2010237130A AU2010237130B2 AU 2010237130 B2 AU2010237130 B2 AU 2010237130B2 AU 2010237130 A AU2010237130 A AU 2010237130A AU 2010237130 A AU2010237130 A AU 2010237130A AU 2010237130 B2 AU2010237130 B2 AU 2010237130B2
Authority
AU
Australia
Prior art keywords
promoter
tumor
cells
mesenchymal stem
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010237130A
Other languages
English (en)
Other versions
AU2010237130A1 (en
Inventor
Peter Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apceth GmbH and Co KG
Original Assignee
Apceth GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth GmbH and Co KG filed Critical Apceth GmbH and Co KG
Publication of AU2010237130A1 publication Critical patent/AU2010237130A1/en
Application granted granted Critical
Publication of AU2010237130B2 publication Critical patent/AU2010237130B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2010237130A 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors Ceased AU2010237130B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16878709P 2009-04-13 2009-04-13
US61/168,787 2009-04-13
PCT/EP2010/054844 WO2010119039A1 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Publications (2)

Publication Number Publication Date
AU2010237130A1 AU2010237130A1 (en) 2011-11-03
AU2010237130B2 true AU2010237130B2 (en) 2015-01-29

Family

ID=42270435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010237130A Ceased AU2010237130B2 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Country Status (12)

Country Link
US (2) US9434925B2 (cg-RX-API-DMAC7.html)
EP (1) EP2419113B1 (cg-RX-API-DMAC7.html)
JP (1) JP5727458B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120088542A (cg-RX-API-DMAC7.html)
CN (1) CN102695517B (cg-RX-API-DMAC7.html)
AU (1) AU2010237130B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1013771A2 (cg-RX-API-DMAC7.html)
CA (1) CA2758120C (cg-RX-API-DMAC7.html)
IL (1) IL215581A0 (cg-RX-API-DMAC7.html)
RU (1) RU2539099C2 (cg-RX-API-DMAC7.html)
SG (1) SG175127A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010119039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
US20130203166A1 (en) * 2012-02-06 2013-08-08 Protobios Llc Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
ES2748662T3 (es) * 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2015100268A1 (en) * 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
CA2936483A1 (en) * 2014-01-17 2015-07-23 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents
CA2956987C (en) * 2014-08-18 2023-03-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
CA3003133C (en) * 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
EP3262159B1 (en) * 2015-02-27 2019-07-24 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cell expressing klotho
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
WO2017036925A1 (en) * 2015-08-28 2017-03-09 Apceth Gmbh & Co. Kg Mesenchymal stem cells for the treatment of metastatic liver disease
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7260898B2 (ja) 2016-01-15 2023-04-19 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ガンマデルタｔ細胞の活性化のための方法および組成物
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
AU2017277499B2 (en) 2016-06-07 2022-07-28 The Pacific Heart, lung & Blood Institute Compositions and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
WO2018009246A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
KR20190109389A (ko) 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
KR102737836B1 (ko) 2017-04-03 2024-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 조성물 및 방법
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP2021526865A (ja) * 2018-06-14 2021-10-11 ロマ・リンダ・ユニヴァーシティ 急性骨髄性白血病の処置のための操作された造血幹細胞
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
KR20210091740A (ko) 2018-11-06 2021-07-22 카리디 바이오테라퓨틱스, 인크. 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
SG10201902002SA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Non-viral modification of mesenchymal stem cells
EP4017512B1 (en) * 2019-08-23 2025-04-02 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
JP2023547728A (ja) 2020-11-06 2023-11-13 アーテック メディカル ジーエムビーエイチ 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物
EP3995130A1 (en) 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7098185B2 (en) * 1998-05-18 2006-08-29 University College London Polypeptide hormone phosphatonin
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
US20030165579A1 (en) * 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
JP2006194752A (ja) * 2005-01-14 2006-07-27 Sumitomo Metal Mining Co Ltd Ｘ線回折測定における試料固定方法および試料固定具
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
EP2851422A3 (en) 2007-05-24 2015-06-24 Apceth GmbH & Co. KG CD34neg stem cells for the treatment of gastrointestinal disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CONRAD, C., et al., "Genetically Engineered Stem Cells for Therapeutic Gene Delivery," Current Gene Therapy, 2007, Vol. 7, pages 249-260. *
MILETIC, H., et al., "Bystander Killing of Malignant Glioma by Bone Marrow-derived Tumor-Infiltrating Progenitor Cells Expressing a Suicide Gene," Molecular Therapy, 2007, Vol. 15, No. 7, pages 1373-1381. *
VILALTA, M., et al., "Human adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander effect: a model based on bioluminescence imaging," Gene Therapy, April 2009, Vol. 16, No. 4, pages 547-557. *

Also Published As

Publication number Publication date
US20120087901A1 (en) 2012-04-12
JP2012523243A (ja) 2012-10-04
EP2419113A1 (en) 2012-02-22
AU2010237130A1 (en) 2011-11-03
JP5727458B2 (ja) 2015-06-03
BRPI1013771A2 (pt) 2016-04-05
WO2010119039A1 (en) 2010-10-21
US20170015976A1 (en) 2017-01-19
EP2419113B1 (en) 2017-05-10
IL215581A0 (en) 2011-12-29
CN102695517A (zh) 2012-09-26
KR20120088542A (ko) 2012-08-08
RU2011146048A (ru) 2013-05-20
RU2539099C2 (ru) 2015-01-10
US9434925B2 (en) 2016-09-06
SG175127A1 (en) 2011-11-28
CA2758120A1 (en) 2010-10-21
CN102695517B (zh) 2015-01-28
CA2758120C (en) 2014-08-19

Similar Documents

Publication Publication Date Title
AU2010237130B2 (en) Engineered mesenchymal stem cells and method of using same to treat tumors
US11464806B2 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
Bajetto et al. Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies
Oggu et al. Gene delivery approaches for mesenchymal stem cell therapy: strategies to increase efficiency and specificity
Zischek et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma
Cole et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells
KR20220095223A (ko) 조작된 조절 t 세포 생성
Namba et al. Use of genetically engineered stem cells for glioma therapy
Li et al. Integrin β1 increases stem cell survival and cardiac function after myocardial infarction
KR20220140542A (ko) 제핵 세포의 생체공학적 제조를 위한 방법 및 용도
Benabdallah et al. Natural killer cells prevent the formation of teratomas derived from human induced pluripotent stem cells
Bahrambeigi et al. Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation
CN116801890A (zh) 用于增强治疗性免疫细胞功效的方法和组合物
Wang et al. Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles
Maliha et al. The role of mesenchymal stem cells in oncology and regenerative medicine
Ebrahimi et al. Drug delivery using genetically modified mesenchymal stem cells: a promising targeted-delivery method
Fukutani et al. Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity
Annese et al. Endothelial progenitor cells from bench to antitumor therapy and diagnostic imaging
da Silva Genetic engineering of Mesenchymal Stromal Cells to express anti-cancer proteins
Kerrigan et al. Mesenchymal Stem/Stromal Cell Recruitment by Central Nervous System Tumors
Lee Engineering Macrophages for Cell-Based Therapies
Jung et al. Genetically Engineered Mesenchymal Stem Cells for Cell and Gene Therapy
Jackson The expansion and transduction of hematopoietic stem cells for gene therapy
Thrasher A dose escalation study of cyclophosphamide (CTX) to enhance SB-728-T engraftment Dale Ando Sangamo BioSciences, Richmond CA, USA
HK1233546B (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired